Van ECK Associates Corp boosted its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 12.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,146 shares of the company's stock after buying an additional 4,973 shares during the period. Van ECK Associates Corp owned approximately 0.08% of argenx worth $17,555,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the business. Parkside Financial Bank & Trust bought a new position in argenx during the third quarter valued at $28,000. FNY Investment Advisers LLC bought a new position in argenx in the 4th quarter valued at $38,000. Nkcfo LLC increased its stake in argenx by 22.1% in the third quarter. Nkcfo LLC now owns 116 shares of the company's stock worth $57,000 after purchasing an additional 21 shares during the period. Toronto Dominion Bank lifted its position in shares of argenx by 174.2% during the third quarter. Toronto Dominion Bank now owns 266 shares of the company's stock worth $131,000 after purchasing an additional 169 shares during the last quarter. Finally, Steph & Co. purchased a new stake in shares of argenx during the third quarter valued at $148,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Piper Sandler raised their price target on shares of argenx from $518.00 to $522.00 and gave the stock an "overweight" rating in a research note on Friday, January 26th. Wedbush reiterated an "outperform" rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. Wells Fargo & Company raised their price objective on argenx from $472.00 to $478.00 and gave the stock an "overweight" rating in a report on Tuesday, February 20th. Wolfe Research assumed coverage on argenx in a research note on Thursday, February 15th. They set a "peer perform" rating on the stock. Finally, Truist Financial lifted their price target on argenx from $370.00 to $440.00 and gave the company a "buy" rating in a report on Tuesday, March 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $528.16.
Read Our Latest Report on argenx
argenx Trading Up 2.6 %
ARGX stock traded up $10.08 on Thursday, hitting $393.42. The company's stock had a trading volume of 210,271 shares, compared to its average volume of 312,362. argenx SE has a 1 year low of $327.73 and a 1 year high of $550.76. The stock has a market cap of $23.38 billion, a price-to-earnings ratio of -74.75 and a beta of 0.67. The firm has a 50 day moving average of $384.46 and a two-hundred day moving average of $413.84.
argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The business had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter last year, the company posted ($0.70) EPS. As a group, equities analysts forecast that argenx SE will post -2.09 EPS for the current fiscal year.
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
